Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author holds a long position in BFLY.
← Back to Free Index

BFLY

Analysis as of: 2026-05-21
Butterfly Network, Inc.
Butterfly sells handheld ultrasound devices and related cloud workflow, AI, education, and developer tools to clinicians, health systems, educators, and partners.
ai enterprise healthcare medical devices software
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

A real device moat still needs platform proof
The company has enough product, margin, and channel momentum to justify a constructive 5-year view. The upside now depends less on invention and more on proving that software, home-care, and Embedded can become repeatable growth engines.

Analysis

Thesis
Butterfly has a credible 5-year path from a handheld-ultrasound vendor to a higher-quality imaging platform if it converts iQ3 adoption, enterprise workflow, home/community care, and Embedded into repeatable recurring revenue before incumbents bundle away the software layer.
Last Economy Alignment
AI should widen who can use ultrasound and where it can be used, while Butterfly owns real hardware, regulatory, and workflow control points. It benefits from cheaper cognition, but it is not the core compute or platform bottleneck of the AI economy.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
2.5x (from 5 most recent analyses)
Reasoning
The upside is real but not open-ended. Butterfly already has a shipping product, improving gross margin, and multiple monetization paths, so the question is not invention but repeatability. A good outcome is a broader imaging platform with more software, workflow, and licensing mix; a great outcome would need much stronger proof than is visible today. That supports a 2-5x setup over five years rather than a 10x claim.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The main risk is not product validity; Butterfly has that. The real risk is whether higher-margin layers become repeatable before incumbents, procurement friction, or regulation compress the opportunity. Home/community care proof, Embedded diversification, and clearer recurring software capture are the three most important gates.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.40
They control a real handheld imaging device, the software around it, and some of the compliance gates that buyers care about, so cheaper AI should make their product useful in more places. The risk is that bigger imaging companies can bundle similar workflow features faster than Butterfly proves its newer channels truly scale.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$5.69
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case